Trial Information

Summary: A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Administration of Omiganan 1.0% Gel in Preventing Local Catheter Site Infections and Catheter Colonization in Patients Undergoing Central Venous Catheterization.

To demonstrate the effectiveness of omiganan 1.0% gel compared to 10% povidone-iodine in preventing local catheter site infections (LCSI) in patients requiring at least one central venous catheter. LCSI will be determined by a blinded Evaluation Committee (EC). The primary efficacy endpoint is the incidence of LCSI prior to study discharge (at early termination, removal of the final study catheter, or study day 28) among survivors.

See www..hsc.wvu.edu/mbrcc/ctru/ for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:45:53 AM